Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Share-based Compensation: 2019-2025

Historic Share-based Compensation for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $22.7 million.

  • Beam Therapeutics' Share-based Compensation fell 23.05% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.0 million, marking a year-over-year decrease of 8.00%. This contributed to the annual value of $120.7 million for FY2024, which is 22.32% up from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Share-based Compensation is $22.7 million, which was down 6.65% from $24.4 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Share-based Compensation peaked at $31.6 million during Q2 2024, and registered a low of $4.6 million during Q1 2021.
  • Its 3-year average for Share-based Compensation is $26.6 million, with a median of $26.3 million in 2023.
  • Per our database at Business Quant, Beam Therapeutics' Share-based Compensation skyrocketed by 330.54% in 2021 and then fell by 23.05% in 2025.
  • Quarterly analysis of 5 years shows Beam Therapeutics' Share-based Compensation stood at $15.5 million in 2021, then skyrocketed by 45.14% to $22.5 million in 2022, then rose by 0.52% to $22.6 million in 2023, then soared by 33.61% to $30.2 million in 2024, then decreased by 23.05% to $22.7 million in 2025.
  • Its Share-based Compensation was $22.7 million in Q3 2025, compared to $24.4 million in Q2 2025 and $26.7 million in Q1 2025.